Latest On Enlivex Therapeutics Ltd (ENLV):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-19 10:10 EST | News | Enlivex stock soars on upcoming US patent linked to cell therapy Allocetra | N/A |  |
| 2023-02-23 14:16 EST | News | Enlivex's trial of cell therapy Allocetra for tumors gets clearance in Spain | N/A | |
| 2023-01-25 16:17 EST | News | Enlivex cleared to expand clinical trial for cell therapy candidate | N/A | |
| 2023-01-04 18:53 EST | News | Enlivex gets French and Belgian regulatory nod to expand mid-stage sepsis trial | N/A | |
| 2022-09-30 16:39 EST | News | Enlivex Therapeutics: A Very Enticing Early-Stage Biotech | N/A | |
| 2022-09-17 02:49 EST | News | Enlivex Therapeutics (ENLV) Investor Presentation - Slideshow | N/A | |
| 2022-09-07 01:12 EST | News | Enlivex to gets US patent covering use of cell therapy Allocetra | N/A | |
| 2022-08-29 11:50 EST | News | Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells | N/A | |
| 2022-07-06 21:47 EST | News | Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment | N/A | |
| 2022-06-06 20:01 EST | News | Enlivex gets Israeli nod to start phase 1/2 Allocetra trial for treating peritoneal cancer | N/A | |
| 2022-05-06 02:25 EST | News | Enlivex gets 2 US patents for treating sepsis with cell therapy Allocetra | N/A | |
| 2022-04-30 00:09 EST | News | Envilex Therapeutics reports FY results | N/A | |
| 2021-11-22 23:29 EST | News | Envilex Therapeutics reports Q3 results | N/A | |
| 2021-11-11 05:16 EST | News | Enlivex granted regulatory nod in Spain for mid-stage trial for COVID-19 therapy | N/A | |
| 2021-10-06 06:07 EST | News | Enlivex gets notice of allowance for Israeli patent application covering Allocetra | N/A | |
| 2021-10-05 03:39 EST | News | Enlivex announces publication of early-stage data for cell therapy in sepsis | N/A | |
| 2021-09-23 02:02 EST | News | Enlivex gets dosing underway in mid-stage Allocetra COVID-19 trial | N/A | |
| 2021-08-16 17:09 EST | News | Enlivex to launch Phase IIb Allocetra trial for COVID-19 patients in Israel | N/A | |
| 2021-08-10 03:15 EST | News | Envilex Therapeutics reports Q2 results | N/A | |
| 2021-07-21 06:55 EST | News | Enlivex issued new Canadian patent for Allocetra immunotherapy | N/A | |
| 2021-07-21 06:45 EST | News | Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy | N/A | |
| 2021-03-30 05:29 EST | News | Enlivex: Interesting Macrophage Reprogramming Science Targets $33B Sepsis Market | N/A | |
| 2021-03-23 02:17 EST | News | Enlivex enters Allocetra research collaboration with Yale Cancer Center | N/A | |
| 2021-03-08 21:04 EST | News | Enlivex gets notice of allowance for Allocetra Japanese patent application | N/A | |
| 2021-03-03 11:34 EST | Analyst Rating | The Analyst Target Price has increased from $22 to $33. | Buy | |
| 2021-03-01 16:43 EST | News | Enlivex and Mount Sinai Health System announce research collaboration deal | N/A | |
| 2021-03-01 16:43 EST | News | Enlivex and Mount Sinai to explore potential of Allocetra with checkpoint inhibitors | N/A | |
| 2021-02-17 02:49 EST | News | Enlivex nabs new U.S. patent for Allocetra, shares up 6% | N/A | |
| 2021-02-10 10:38 EST | News | Enlivex Therapeutics slumps 10% on $10M capital raise | N/A | |
| 2021-02-10 10:37 EST | News | Enlivex Therapeutics shares down 9% on capital raise via equity offering | N/A | |
| 2021-02-03 18:31 EST | News | Enlivex shares rise 20% on positive Allocetra data in COVID-19 | N/A | |
| 2020-12-04 00:36 EST | News | Enlivex Therapeutics rises on interim Allocetra data in mid-stage COVID-19 study | N/A | |
| 2020-11-26 19:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 15:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-04 19:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-04 01:03 EST | News | Enlivex on go with late-stage study of Allocetra for sepsis | N/A | |
| 2020-11-03 15:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 07:39 EST | Earnings Estimate | An EPS average of -$0.22 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-10-22 21:59 EST | News | Mid-stage study underway testing Enlivex's Allocetra in COVID-19 patients | N/A | |
| 2020-10-16 19:20 EST | News | Enlivex (ENLV) Investor Presentation - Slideshow | N/A | |
| 2020-10-14 12:09 EST | News | Enlivex on go with mid-stage study with Allocetra for COVID-19 | N/A | |
| 2020-10-01 10:42 EST | News | Enlivex +5% on positive Allocetra results in COVID-19 | N/A | |
| 2020-09-26 12:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-16 12:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 08:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-10 11:33 EST | News | Study underway on Enlivex's Allocetra in COVID-19 | N/A | |
| 2020-07-31 00:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 08:37 EST | Financials | Company financials have been released. | Neutral | |
About Enlivex Therapeutics Ltd (ENLV):
Enlivex Therapeutics Ltd operates as a clinical stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and various others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
General
- Name Enlivex Therapeutics Ltd
- Symbol ENLV
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 36
- Last Split Factor1:8
- Last Split Date2019-03-06
- Fiscal Year EndDecember
- IPO Date1995-12-12
- Gic SectorInformation Technology
- Gic GroupSoftware & Services
- Gic IndustrySoftware
- Gic SubIndustryApplication Software
- Web URLhttp://www.enlivex.com
View More
Valuation
- Price/Book (Most Recent Quarter) 8.69
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.28
- Return on Assets -21%
- Return on Equity -42%
- Earnings Per Share -$1.42
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 235.87 million
- EBITDA -6807000
- Analyst Target Price $33
- Book Value Per Share $2.12
View More
Share Statistics
- Shares Outstanding 18.23 million
- Shares Float 9.24 million
- % Held by Insiders 3352%
- % Held by Institutions 13.47%
- Shares Short 95191
- Shares Short Prior Month 57868
- Short Ratio 0.1
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- 52 Week High $29.4
- 52 Week Low $3.78
- 50 Day Moving Average 15.87
- 200 Day Moving Average 11.09
View More
Dividends
- Dividend Date 2019-03-06
- ExDividend Date N/A
- Dividend Yield 0%
View More
Enlivex Therapeutics Ltd (ENLV) Dividend Calendar:
ENLV's last dividend payment was made to shareholders on March 6, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Enlivex Therapeutics Ltd (ENLV) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-10-30 | $N/A | -$0.16 | -$0.18 | 11.11% |
| 2020-06-30 | 2020-08-14 | $N/A | -$0.23 | -$0.24 | 4.17% |
| 2020-03-31 | 2020-05-18 | $N/A | -$0.07 | -$0.24 | 70.83% |
| 2019-12-31 | 2020-02-21 | $N/A | -$0.28 | -$0.25 | -12% |
| 2019-09-30 | 2019-11-14 | $N/A | -$0.23 | ||
| 2019-06-30 | 2019-07-26 | $N/A | -$0.14 | ||
| 2019-03-31 | 2019-04-30 | $N/A | -$0.69 | ||
| 2017-12-31 | 2018-02-23 | $N/A | -$1.36 | ||
| 2017-09-30 | 2017-11-02 | $N/A | -$2.56 | ||
| 2017-06-30 | 2017-08-04 | -$3.97 | |||
| 2017-03-31 | 2017-05-26 | -$6.40 | -$11.60 | 44.83% | |
| 2016-12-31 | 2017-02-24 | -$7.60 | -$10.80 | 29.63% | |
| 2016-09-30 | 2016-11-29 | -$11.20 | -$8.80 | -27.27% | |
| 2016-06-30 | 2016-08-25 | -$1.10 | -$0.27 | -307.41% | |
| 2016-03-31 | 2016-05-25 | -$1.60 | -$0.28 | -471.43% | |
| 2015-12-31 | 2016-02-23 | -$0.34 | -$0.25 | -36% | |
| 2015-09-30 | 2015-11-17 | -$0.25 | -$0.29 | 13.79% | |
| 2015-06-30 | 2015-08-21 | -$0.26 | -$0.28 | 7.14% | |
| 2015-03-31 | 2015-05-19 | -$0.23 | -$0.24 | 4.17% | |
| 2014-12-31 | 2015-02-17 | -$0.22 | -$0.15 | -46.67% | |
| 2014-09-30 | 2014-11-21 | -$0.16 | -$0.08 | -100% | |
| 2014-06-30 | 2014-08-29 | -$4.04 |
Enlivex Therapeutics Ltd (ENLV) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Enlivex Therapeutics Ltd (ENLV) Chart:
Enlivex Therapeutics Ltd (ENLV) News:
Below you will find a list of latest news for Enlivex Therapeutics Ltd (ENLV) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Enlivex Therapeutics Ltd (ENLV) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.05 | CALL | 9 | 1111 | 177.51 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.05 | CALL | 0 | 719 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.6 | CALL | 0 | 178 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 1.25 | PUT | 0 | 146 | 249.39 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 2.15 | PUT | 0 | 31 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 2.75 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.1 | CALL | 0 | 42 | 162.96 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 182.14 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 271.85 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 349.26 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.19 | CALL | 6 | 13 | 127.81 | FALSE | 0.19 | 0 |
| 2024-08-16 | 5 | 0.05 | CALL | 0 | 82 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0.05 | CALL | 0 | 7 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 1.37 | PUT | 0 | 5 | 141.06 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 217.73 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 487.7 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 0 | CALL | 0 | 0 | 135.95 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 7.5 | 0.45 | CALL | 0 | 86 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 1.37 | PUT | 0 | 85 | 213.87 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | PUT | 0 | 0 | 182.05 | TRUE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | PUT | 0 | 0 | 215.18 | TRUE | 0 | 0 |
Latest ENLV Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 2:21 PM EST | 100 | $3.95 |
| Jun 13, 2022 2:21 PM EST | 15 | $3.95 |
| Jun 13, 2022 4:47 PM EST | 100 | $3.94 |
| Jun 13, 2022 7:19 PM EST | 100 | $3.91 |
| Jun 13, 2022 7:19 PM EST | 30 | $3.92 |
Enlivex Therapeutics Ltd (ENLV) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020016038/0001213900-20-016038-index.htm |
| 2019-06-13 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1596812/000000000019009813/0000000000-19-009813-index.htm |
| 2019-07-03 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1596812/000000000019010744/0000000000-19-010744-index.htm |
| 2019-12-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1596812/000000000019016335/0000000000-19-016335-index.htm |
| 2020-01-27 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1596812/000000000020000675/0000000000-20-000675-index.htm |
| 2020-02-03 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1596812/000000000020000993/0000000000-20-000993-index.htm |
| 2016-03-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416088910/0001144204-16-088910-index.htm |
| 2016-03-29 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416090954/0001144204-16-090954-index.htm |
| 2016-03-29 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1596812/000114420416090970/0001144204-16-090970-index.htm |
| 2016-04-01 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1596812/000114420416092293/0001144204-16-092293-index.htm |
| 2016-05-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416104795/0001144204-16-104795-index.htm |
| 2016-06-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416107593/0001144204-16-107593-index.htm |
| 2016-06-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416109537/0001144204-16-109537-index.htm |
| 2016-07-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416111498/0001144204-16-111498-index.htm |
| 2016-08-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416117432/0001144204-16-117432-index.htm |
| 2016-08-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416121117/0001144204-16-121117-index.htm |
| 2016-09-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416123508/0001144204-16-123508-index.htm |
| 2016-10-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416129194/0001144204-16-129194-index.htm |
| 2016-11-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420416136825/0001144204-16-136825-index.htm |
| 2017-01-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417002553/0001144204-17-002553-index.htm |
| 2017-02-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417010801/0001144204-17-010801-index.htm |
| 2017-02-24 | F-1 | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1596812/000114420417011003/0001144204-17-011003-index.htm |
| 2017-02-24 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417011029/0001144204-17-011029-index.htm |
| 2017-03-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417013987/0001144204-17-013987-index.htm |
| 2017-03-16 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1596812/000114420417014840/0001144204-17-014840-index.htm |
| 2017-04-04 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1596812/000114420417018878/0001144204-17-018878-index.htm |
| 2017-04-05 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1596812/000114420417019259/0001144204-17-019259-index.htm |
| 2017-04-06 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1596812/000114420417019315/0001144204-17-019315-index.htm |
| 2017-04-06 | RW | Registration Withdrawal Request | https://www.sec.gov/Archives/edgar/data/1596812/000114420417019411/0001144204-17-019411-index.htm |
| 2017-04-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417020795/0001144204-17-020795-index.htm |
| 2017-05-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417029879/0001144204-17-029879-index.htm |
| 2017-06-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417031150/0001144204-17-031150-index.htm |
| 2017-08-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417040598/0001144204-17-040598-index.htm |
| 2017-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417043151/0001144204-17-043151-index.htm |
| 2017-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417048497/0001144204-17-048497-index.htm |
| 2017-09-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417049350/0001144204-17-049350-index.htm |
| 2017-10-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417052503/0001144204-17-052503-index.htm |
| 2017-11-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417055656/0001144204-17-055656-index.htm |
| 2017-11-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417059704/0001144204-17-059704-index.htm |
| 2017-12-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420417064622/0001144204-17-064622-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000114420418008293/0001144204-18-008293-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000114420418008296/0001144204-18-008296-index.htm |
| 2018-04-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420418019609/0001144204-18-019609-index.htm |
| 2018-04-23 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1596812/000114420418021827/0001144204-18-021827-index.htm |
| 2018-07-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420418040158/0001144204-18-040158-index.htm |
| 2018-11-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420418060786/0001144204-18-060786-index.htm |
| 2018-11-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420418061240/0001144204-18-061240-index.htm |
| 2018-12-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420418063390/0001144204-18-063390-index.htm |
| 2018-12-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420418066396/0001144204-18-066396-index.htm |
| 2018-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420418066751/0001144204-18-066751-index.htm |
| 2019-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420419004123/0001144204-19-004123-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000114420419007522/0001144204-19-007522-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000114420419007701/0001144204-19-007701-index.htm |
| 2019-02-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420419008747/0001144204-19-008747-index.htm |
| 2019-02-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420419008901/0001144204-19-008901-index.htm |
| 2019-03-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420419012426/0001144204-19-012426-index.htm |
| 2019-03-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420419014465/0001144204-19-014465-index.htm |
| 2019-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000114420419016097/0001144204-19-016097-index.htm |
| 2019-04-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019005994/0001213900-19-005994-index.htm |
| 2019-04-30 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019007437/0001213900-19-007437-index.htm |
| 2019-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019009207/0001213900-19-009207-index.htm |
| 2019-05-31 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1596812/000121390019009859/0001213900-19-009859-index.htm |
| 2019-06-07 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1596812/000121390019010285/0001213900-19-010285-index.htm |
| 2019-06-19 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1596812/000121390019011007/0001213900-19-011007-index.htm |
| 2019-06-19 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000121390019011017/0001213900-19-011017-index.htm |
| 2019-06-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000121390019011480/0001213900-19-011480-index.htm |
| 2019-06-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000121390019011491/0001213900-19-011491-index.htm |
| 2019-06-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000121390019011604/0001213900-19-011604-index.htm |
| 2019-06-28 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1596812/000121390019011719/0001213900-19-011719-index.htm |
| 2019-07-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1596812/000121390019012138/0001213900-19-012138-index.htm |
| 2019-07-10 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019012388/0001213900-19-012388-index.htm |
| 2019-07-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019012795/0001213900-19-012795-index.htm |
| 2019-07-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019013728/0001213900-19-013728-index.htm |
| 2019-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019016228/0001213900-19-016228-index.htm |
| 2019-09-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019017460/0001213900-19-017460-index.htm |
| 2019-09-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000121390019017495/0001213900-19-017495-index.htm |
| 2019-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019019242/0001213900-19-019242-index.htm |
| 2019-10-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019020960/0001213900-19-020960-index.htm |
| 2019-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019021895/0001213900-19-021895-index.htm |
| 2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019023314/0001213900-19-023314-index.htm |
| 2019-11-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390019024223/0001213900-19-024223-index.htm |
| 2020-01-23 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020001652/0001213900-20-001652-index.htm |
| 2020-01-31 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020002280/0001213900-20-002280-index.htm |
| 2020-01-31 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1596812/000121390020002282/0001213900-20-002282-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000121390020003723/0001213900-20-003723-index.htm |
| 2020-02-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020004554/0001213900-20-004554-index.htm |
| 2020-02-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020004780/0001213900-20-004780-index.htm |
| 2020-02-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020004819/0001213900-20-004819-index.htm |
| 2020-03-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020005319/0001213900-20-005319-index.htm |
| 2020-03-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020005465/0001213900-20-005465-index.htm |
| 2020-03-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020006736/0001213900-20-006736-index.htm |
| 2020-04-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020009028/0001213900-20-009028-index.htm |
| 2020-04-30 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/0001213900-20-010632-index.htm |
| 2020-05-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020011244/0001213900-20-011244-index.htm |
| 2020-05-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020012831/0001213900-20-012831-index.htm |
| 2020-05-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020012880/0001213900-20-012880-index.htm |
| 2020-05-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020013571/0001213900-20-013571-index.htm |
| 2020-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020014910/0001213900-20-014910-index.htm |
| 2020-06-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020015233/0001213900-20-015233-index.htm |
| 2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020016038/0001213900-20-016038-index.htm |
| 2020-08-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020021034/0001213900-20-021034-index.htm |
| 2020-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020022278/0001213900-20-022278-index.htm |
| 2020-08-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020023563/0001213900-20-023563-index.htm |
| 2020-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020026840/0001213900-20-026840-index.htm |
| 2020-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020029393/0001213900-20-029393-index.htm |
| 2020-10-13 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020030994/0001213900-20-030994-index.htm |
| 2020-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020030996/0001213900-20-030996-index.htm |
| 2020-10-22 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020032705/0001213900-20-032705-index.htm |
| 2020-10-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020032707/0001213900-20-032707-index.htm |
| 2020-10-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020032709/0001213900-20-032709-index.htm |
| 2020-10-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020033377/0001213900-20-033377-index.htm |
| 2020-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020034267/0001213900-20-034267-index.htm |
| 2020-11-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020034669/0001213900-20-034669-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1596812/000121390020035155/0001213900-20-035155-index.htm |
| 2017-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000138713117000864/0001387131-17-000864-index.htm |
| 2016-03-23 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000153561016000142/0001535610-16-000142-index.htm |
| 2017-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1596812/000153561017000037/0001535610-17-000037-index.htm |
| 2019-06-21 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1596812/999999999519001408/9999999995-19-001408-index.htm |
| 2019-07-09 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1596812/999999999519001550/9999999995-19-001550-index.htm |